A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  King, Thomas H ^a   Kemmler, Charles B ^a,b   Guo, Zhimin ^a   Mann, Derrick ^a   Lu, Yingnian ^a   Coeshott, Claire ^a   Gehring, Adam J ^d,e   Bertoletti, Antonio ^e   Ho, Zi Z ^e   Delaney, William ^c   Gaggar, Anuj ^c   Subramanian, G Mani ^c   McHutchison, John G ^c   Shrivastava, Shikha ^f   Lee, Yu Jin L ^f   Kottilil, Shyamasundaran ^f   Bellgrau, Donald ^a,b   Rodell, Timothy ^a   Apelian, David ^a  

^a GlobeImmune Inc   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c GILEAD SCIENCES   (United States)

^d Saint Louis University   (United States)

^e AGENCY FOR SCIENCE   (Singapore)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAMMA INTERFERON; GS 4774; HEPATITIS B ANTIGEN; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B X ANTIGEN; INTERLEUKIN 2; OVAX; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; CORE PROTEIN; HEPATITIS B VIRUS X PROTEIN; TRANSACTIVATOR PROTEIN; VIRUS FUSION PROTEIN;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL ISOLATION; CELL MATURATION; CELLULAR IMMUNITY; CYTOLYSIS; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; HEPATITIS B; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; IMMUNOTHERAPY; INCUBATION TIME; INTRACELLULAR CYTOKINE STAINING; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; STAINING; T LYMPHOCYTE; TARGETED MOLECULAR IMMUNOGEN; TH1 CELL; VIRAL CLEARANCE; VIRUS EXPRESSION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL CULTURE; CELL PROLIFERATION; CROSS PRESENTATION; FEMALE; GENETICS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; IMMUNOLOGY; LIVER TUMOR; METABOLISM; SACCHAROMYCES CEREVISIAE; SCID MOUSE; VACCINATION; VIROLOGY;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; CROSS-PRIMING; DENDRITIC CELLS; FEMALE; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-2; LIVER NEOPLASMS; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, SCID; SACCHAROMYCES CEREVISIAE; T-LYMPHOCYTES; TRANS-ACTIVATORS; VACCINATION; VIRAL CORE PROTEINS; VIRAL FUSION PROTEINS;

EID: 84904625418     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101904     Document Type: Article

References (45)

1. Chen L-P, Zhao J, Du Y, Han Y-F, Su T, et al. (2012) Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma. World J Virol 1: 174-183.
2. Rehermann B (2013) Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med 19: 859-868.
3. Fletcher S, Delaney W (2013) New Therapeutic Targets and Drugs for the Treatment of Chronic Hepatitis B. Semin Liver Dis 33: 130-137.
4. Lok AS-F (2013) Hepatitis: Long-term therapy of chronic hepatitis B reverses cirrhosis. Nat Rev Gastroenterol Hepatol 10: 199-200.
5. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, et al. (2013) Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381: 468-475.
6. Bertoletti A, Ferrari C (2012) Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 61: 1754-1764.
7. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, et al. (1999) Viral clearance without destruction of infected cells during acute HBV infection. Science 284: 825-829. (Pubitemid 29291352)
8. Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, et al. (2003) CD8 + T Cells Mediate Viral Clearance and Disease Pathogenesis during Acute Hepatitis B Virus Infection J Virol. 77: 68-76. (Pubitemid 36004947)
9. Phillips S, Chokshi S, Riva A, Evans A, Williams R, et al. (2010) CD8(+) T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions. J Immunol 184: 287-295.
10. Menne S, Tennant BC, Gerin JL, Cote PJ (2007) Chemoimmunotherapy of chronic hepatitis B virus infection in the woodchuck model overcomes immunologic tolerance and restores T-cell responses to pre-S and S regions of the viral envelope protein. J Virol 81: 10614-10624. (Pubitemid 47463335)
11. Evans A, Riva A, Cooksley H, Phillips S, Puranik S, et al. (2008) Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion. Hepatology 48: 759-769.
12. Maini MK, Schurich A (2010) The molecular basis of the failed immune response in chronic HBV: therapeutic implications. J Hepatol 52: 616-619.
13. Sherman AC, Trehanpati N, Daucher M, Davey RT, Masur H, et al. (2013) Augmentation of Hepatitis B Virus-Specific Cellular Immunity with Programmed Death Receptor-1/Programmed Death Receptor-L1 Blockade in Hepatitis B Virus and HIV/Hepatitis B Virus Coinfected Patients Treated with Adefovir. AIDS Res Hum Retroviruses 29: 665-672.
14. Stubbs AC, Martin KS, Coeshott C, Skaates SV, Kuritzkes DR, et al. (2001) Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nat Med 7: 625-629. (Pubitemid 32448332)
15. Wansley EK, Chakraborty M, Hance KW, Bernstein MB, Boehm AL, et al. (2008) Vaccination with a recombinant Saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses. Clin Cancer Res 14: 4316-4325.
16. Haller A, Lauer GM, King TH, Kemmler C, Fiolkoski V, et al. (2007) Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. Vaccine 25: 1452-1463. (Pubitemid 46074294)
17. Cereda V, Vergati M, Huen N-Y, di Bari MG, Jochems C, et al. (2011) Maturation of human dendritic cells with Saccharomyces cerevisiae (yeast) reduces the number and function of regulatory T cells and enhances the ratio of antigen-specific effectors to regulatory T cells. Vaccine 29: 4992-4999.
18. Benwell RK, Lee DR (2010) Essential and synergistic roles of IL1 and IL6 in human Th17 differentiation directed by TLR ligand-activated dendritic cells. Clin Immunol 134: 178-187.
19. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401.
20. Shiffman ML, Muir AJ, Vierling JM, Gordon SC, Kugelmas M, et al. (2012) GI-5005 Therapeutic vaccine enhances virologic clearance by peg-IFN/ribavirin in naive HCV genotype 1 patients with IL28B genotype T/T (AASLD).
21. Desmond CP, Bartholomeusz A, Gaudieri S, Revill PA, Lewin SR (2008) A systematic review of T-cell epitopes in hepatitis B virus: identification, genotypic variation and relevance to antiviral therapeutics 13: 161-175.
22. Schirmbeck R, Böhm W, Fissolo N, Melber K, Reimann J (2003) Different immunogenicity of H-2 Kb-restricted epitopes in natural variants of the hepatitis B surface antigen. Eur J Immunol 33: 2429-2438. (Pubitemid 37138975)
23. Milich DR, Mclachlan A, Moriarty ANN, Thornton GB (1987) Immune response to hepatitis B virus core antigen (HBcAg): localization of T-cell recognition sites within HBcAg/HBeAg. J Immunol 139: 1223-1231. (Pubitemid 17134185)
24. Gehring AJ, Xue S-A, Ho ZZ, Teoh D, Ruedl C, et al. (2011) Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. J Hepatol 55: 103-110.
25. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, et al. (2006) HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107: 4781-4789. (Pubitemid 43882629)
26. Remondo C, Cereda V, Mostböck S, Sabzevari H, Franzusoff A, et al. (2009) Human dendritic cell maturation and activation by a heat-killed recombinant yeast (Saccharomyces cerevisiae) vector encoding carcinoembryonic antigen. Vaccine 27: 987-994.
27. Bernstein MB, Chakraborty M, Wansley EK, Guo Z, Franzusoff A, et al. (2008) Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells. Vaccine 26: 509-521.
28. Höhn H, Neukirch C, Freitag K, Necker A, Hitzler W, et al. (2002) Longitudinal analysis of the T-cell receptor (TCR)-VA and -VB repertoire in CD8+ T cells from individuals immunized with recombinant hepatitis B surface antigen. Clin Exp Immunol 129: 309-317.
29. Bauer T, Jilg W (2006) Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine 24: 572-577. (Pubitemid 43017822)
30. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, et al. (2003) Sensitive and viable identification of antigen-specific CD8 + T cells by a flow cytometric assay for degranulation. J Immunol Methods 281: 65-78. (Pubitemid 37324571)
31. Chisari FV, Isogawa M, Wieland SF (2010) Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris) 58: 258-266.
32. Bertoletti A, Gehring AJ (2006) The immune response during hepatitis B virus infection. J Gen Virol 87: 1439-1449. (Pubitemid 43827198)
33. Paludan C, Bickham K, Nikiforow S, Tsang ML, Goodman K, et al. (2002) Epstein-Barr nuclear antigen 1-specific CD4(+) Th1 cells kill Burkitt's lymphoma cells. J Immunol 169: 1593-1603. (Pubitemid 34809208)
34. Appay V, Zaunders JJ, Papagno L, Sutton J, Jaramillo A, et al. (2002) Characterization of CD4(+) CTLs ex vivo. J Immunol 168: 5954-5958.
35. Aslan N, Yurdaydin C, Wiegand J, Greten T, Ciner A, et al. (2006) Cytotoxic CD4 T cells in viral hepatitis. J Viral Hepat 13: 505-514. (Pubitemid 44100401)
36. Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, et al. (2007) Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol 81: 4215-4225. (Pubitemid 46586915)
37. Buchmann P, Dembek C, Kuklick L, Jäger C, Tedjokusumo R, et al. (2013) A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice. Vaccine 31: 1197-1203.
38. Kosinska AD, Zhang E, Johrden L, Liu J, Seiz PL, et al. (2013) Combination of DNA prime-adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model. PLoS Pathog 9(6): e1003391.
39. Tamburini BA, Kedl RM, Bellgrau D (2012) IL-6-inducing Whole Yeast-based Immunotherapy Directly Controls IL-12-dependent CD8 T cell responses. 35: 14-22.
40. Shrivastava S, Trehanpati N, Patra S, Kottilil S, Pande C, et al. (2013) Increased regulatory T cells and impaired functions of circulating CD8 T lymphocytes is associated with viral persistence in Hepatitis B virus-positive newborns. J Viral Hepat 20: 582-591.
41. Xu D, Fu J, Jin L, Zhang H, Zhou C, et al. (2006) Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 177: 739-747. (Pubitemid 43939189)
42. Cortez KJ, Proschan MA, Barrett L, Brust DG, Weatherley B, et al. (2013) Baseline CD4+ T-cell counts predict HBV viral kinetics to adefovir treatment in lamivudine-resistant HBV-infected patients with or without HIV infection. HIV Clin Trials 14: 149-159.
43. Jonas MM, Block JM, Haber BA, Karpen SJ, London WT, et al. (2010). Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options. Hepatology. 52: 2192-205.
44. Liu F, Campagna M, Qi Y, Zhao X, Guo F, et al. (2013) Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes. PLOS pathogens (9):e1003613
45. Boehm A, Higgins J, Franzusoff A, Schlom J, Hodge J (2010) Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations. Cancer Immunology and Immunotherapy 59: 397-408.